A double blind, randomized, placebo-controlled phase II study to assess the safety and efficacy of orally administered SP-303 for the symptomatic treatment of diarrhea in patients with AIDS

Objective:The aim of this study was to investigate the safety and effectiveness of orally administered SP-303 in patients with AIDS and diarrhea.Methods:This is a multicenter, phase II, randomized, double blind, placebo-controlled study. HIV-positive subjects with a history of a CD4 count <200 or an AIDS-defining illness were admitted to an inpatient study unit and screened for diarrhea defined as at least three abnormal (i.e., soft or watery) stools and >200 g of abnormal stool weight over a 24-h period. Subjects discontinued all antidiarrheal agents >24 h before enrollment. Stool samples were studied for routine pathogens. Subjects received 500 mg p.o. of SP-303 or placebo every 6 h for 96 h (4 days). Stool frequency and weights were recorded. Subjects were monitored for symptoms and side effects and were seen 1 wk later in follow-up.Results:A total of 26 subjects received SP-303, and 25 received placebo. There were no significant demographic differences between treatment arms. A total of 41 subjects (80%) were receiving antiretroviral therapy and 39 subjects (77%) were receiving at least one protease inhibitor. Stool studies revealed no pathogens in 48 of 51 patients (94%). There were no serious adverse events or laboratory abnormalities. The SP-303 treatment group demonstrated a mean reduction from baseline stool weight of 451 g/24 h versus 150 g/24 h with placebo on day 4 of treatment (p= 0.14), and a mean reduction in abnormal stool frequency of three abnormal stools in 24 h versus two in 24 h in the placebo group (p= 0.30). Daily measures analysis over 4 days of treatment demonstrated that SP-303 subjects had a significant reduction in stool weight (p= 0.008) and abnormal stool frequency (p= 0.04) when compared to placebo-treated subjects.Conclusions:SP-303 is safe and well tolerated. These results suggest that SP-303 may be effective in reducing stool weight and frequency in patients with AIDS and diarrhea.

[1]  B. Gazzard,et al.  Natural history and prognosis of diarrhoea of unknown cause in patients with acquired immunodeficiency syndrome (AIDS). , 1995, Gut.

[2]  A. K. Singh,et al.  Colonic Cl channel blockade by three classes of compounds. , 1991, The American journal of physiology.

[3]  R. Soave,et al.  Agents of diarrhea. , 1997, The Medical clinics of North America.

[4]  D. Kuritzkes,et al.  Human immunodeficiency virus type 1 protease inhibitors. , 1997, Archives of internal medicine.

[5]  Ø. Olsvik,et al.  Vibrio cholerae and Cholera , 1994 .

[6]  E. Rozhon,et al.  A novel plant-derived inhibitor of cAMP-mediated fluid and chloride secretion. , 1999, American journal of physiology. Gastrointestinal and liver physiology.

[7]  P. Reiss,et al.  Improvement of chronic diarrhoea in patients with advanced HIV‐1 infection during potent antiretroviral therapy , 1998, AIDS.

[8]  R. Sakai,et al.  Biologically active natural products , 1990 .

[9]  G. Rabbani.  Mechanism and treatment of diarrhoea due to Vibrio cholerae and Escherichia coli: roles of drugs and prostaglandins. , 1996, Danish medical bulletin.

[10]  John W. Ward,et al.  1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. , 1993, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[11]  Larry K. Pickering,et al.  Infections of the Gastrointestinal Tract , 1980, Current Topics in Infectious Disease.

[12]  G. Marshall,et al.  HIV-associated diarrhoea and wasting Report of a meeting at the University of Texas Medical School at Houston , 1995, The Lancet.

[13]  Rabbani Gh.  Mechanism and treatment of diarrhoea due to Vibrio cholerae and Escherichia coli: roles of drugs and prostaglandins. , 1996 .

[14]  D. Pleskow,et al.  Malabsorption and wasting in AIDS patients with microsporidia and pathogen‐negative diarrhea , 1996, AIDS.

[15]  J. Hudson,et al.  Studies on the pharmacological activity of Amazonian Euphorbiaceae. , 1988, Journal of ethnopharmacology.

[16]  B. Gazzard,et al.  Intestinal inflammation, ileal structure and function in HIV , 1996, AIDS.

[17]  B. Gazzard,et al.  Gastrointestinal manifestations of HIV infection , 1996, The Lancet.

[18]  M. P. Fanti,et al.  Elevated plasma levels of vasoactive intestinal peptide in AIDS patients with refractory idiopathic diarrhoea. Effects of treatment with octreotide , 1993, AIDS.

[19]  J F Fries,et al.  Quality of life and health service use among HIV-infected patients with chronic diarrhea. , 1993, Journal of acquired immune deficiency syndromes.

[20]  S D Imber,et al.  Some conceptual and statistical issues in analysis of longitudinal psychiatric data. Application to the NIMH treatment of Depression Collaborative Research Program dataset. , 1993, Archives of general psychiatry.

[21]  D. Cooper,et al.  Treatment of HIV-1-associated microsporidiosis and cryptosporidiosis with combination antiretroviral therapy , 1998, The Lancet.

[22]  A Brazier,et al.  SP-303, an antiviral oligomeric proanthocyanidin from the latex of Croton lechleri (Sangre de Drago). , 1994, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[23]  J. Cello,et al.  Declining prevalence of cryptosporidiosis in San Francisco. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  G. Marshall,et al.  HIV-associated diarrhoea and wasting , 1995, The Lancet.

[25]  J. Schulzke,et al.  Duodenal biopsies of HIV‐infected patients with diarrhoea exhibit epithelial barrier defects but no active secretion , 1998, AIDS.

[26]  R. N. Blomster,et al.  South American plants II: taspine isolation and anti-inflammatory activity. , 1979, Journal of pharmaceutical sciences.

[27]  F.J. Sauvage,et al.  Activation of intestinal CFTR Cl‐ channel by heat‐stable enterotoxin and guanylin via cAMP‐dependent protein kinase. , 1994, The EMBO journal.

[28]  W. J. Fessel,et al.  Multicenter trial of octreotide in patients with refractory acquired immunodeficiency syndrome-associated diarrhea. , 1995, Gastroenterology.

[29]  J. Schulzke,et al.  Tumor necrosis factor-alpha induces Cl- and K+ secretion in human distal colon driven by prostaglandin E2. , 1996, The American journal of physiology.

[30]  F. J. Lipp,et al.  New Plant Sources for Drugs and Foods from the New York Botanical Garden Herbarium , 1982 .

[31]  B. Gazzard,et al.  Faecal tumour necrosis factor-α in individuals with HIV-related diarrhoea , 1996 .

[32]  John E. Bennett,et al.  Principles and practice of infectious diseases. Vols 1 and 2. , 1979 .